nueva página del texto (beta)
Inglés (pdf)
Artículo en XML
Referencias del artículo
Traducción automática
Enviar artículo por email
Citado por SciELO 
Similares en
SciELO 
Permalink
Introduction
In recent years, deaths related to stroke, the third most common cause of mortality worldwide1, have increased by 26%, whereas the number of stroke survivors has increased by 84%; there are slightly more than 33 million people who are currently living after stroke2. Conversely, cancer is the second most common cause of death, which has shown an increasing trend between 2005 and 2015, with a 17% rise in the number of cancer-related deaths globally1.
One in 10 patients with stroke concurrently has cancer3, and the impact of their combination on survival has not been well established4,5. There are no studies specifically examining the common cardiovascular risk factors and comparing the mortality rates in patients with cancer and stroke. Stroke has been described as the first manifestation of cancer6-8, and it also has been associated with a worse prognosis9, consequently, stroke and cancer are likely to have unrecognized associations, for example, cryptogenic stroke is more frequent in cancer patients10,11. Due to the high prevalence of stroke in cancer patients and vice-versa, we aimed to analyze the stroke risk factors and outcomes in patients with cancer, which were compared with a socio-demographically similar population of stroke patients with no history of cancer, to recognize this as an added hazard element that might impact mortality rates and provide better care and prompt support.
Material and methods
This study included information from a computerized database, which was created in 2010 to collect data of patients with cancer at Instituto Nacional de Cancerología in Mexico City, a cancer referral center, who were followed up during the neuro-oncologic consultation between January 2011 and February 2018. Inclusion criteria considered patients of ≥18 years with histologically confirmed diagnosis of cancer at our institute who showed evidence by magnetic resonance image (MRI) of suffering a stroke during surveillance. Exclusion criteria apply for those with a diagnosis of stroke before cancer. The data included: demographic characteristics, cancer history, stroke characteristics, follow-up duration, and time to death. Stroke type and other characteristics were obtained directly from the registry database, corroborated by MRI, and validated by a board-certified neurologist. Data on age, sex, stroke risk factors (diabetes mellitus, hypertension, hypercholesterolemia, obesity, smoking, and alcohol abuse), and mortality in this cohort were compared to those of patients with no known cancer within a previously reported cohort of stroke patients from the national registry of cerebrovascular disease. The latter cohort was reported in the RENAMEVASC study (2000 stroke patients: 1134 ischemic, 806 hemorrhagic, and 60 cerebral venous thrombosis)12 and PREMIER study (2702 ischemic stroke patients)13 The institutional ethics and investigation committee approved data acquisition (INCAN/CI/837/17) waiving the need for written consent given the characteristics of the study.
Statistical analysis
Comparisons between groups were performed to obtain risk ratios with 95% confidence intervals (CIs). p < 0.001 was used to define statistical significance. To compare ages, Student's t-test was used after determining the mean and standard deviation using Hazen's equation14, where p value is the area of the t distribution with n1 + n2 − 2 degrees of freedom, which falls outside ± t. All statistical analyses were performed with IBM SPSS Statistics for Windows, version 25 (IBM Corp. Armonk, N.Y., USA).
Results
A total of 270 patients with cancer and stroke were compared to a previously assembled cohort of 2000 patients with stroke and no history of cancer. The median follow-up of the cancer patients after the stroke was 13.8 months (interquartile range [IQR] of 1.3–52.4 months); after 12 months of surveillance, 11 patients were lost to follow-up. General characteristics of both cohorts are presented in table 1, with type of cancer and age subgroups details in Supplementary tables 1 and 2 (available online). Briefly, for oncology patients, gynecologic cancer was more frequently observed in ischemic stroke, while hemorrhagic and cerebral venous thrombosis were more frequent in patients with hematologic cancer; subgroup of age <45 years presented higher frequency (50.8%) for hemorrhagic stroke; nonetheless, ischemic stroke leads all ages ≥45 years.
Table 1 General characteristics of patients with cancer compared to a cohort of same populations without cancer14
| Cancer patients n = 270 (%) | Non-cancer patients n = 2,000 (%) | RR (95%CI) | p value | |
|---|---|---|---|---|
| Median age (IQR), years | 58 (46-68) | 64 (49-75) | - | p < 0.0001 |
| Gender | ||||
| Female | 178 (65.9) | 1103 (55.1) | 1.2 (1.08-1.31) | p = 0.0002 |
| Male | 92 (34.1) | 897 (44.9) | 0.76 (0.64-0.9) | p = 0.0018 |
| Stroke type | ||||
| Ischemic | 191 (70.7) | 1,134 (56.7) | 1.25 (1.14-1.36) | p < 0.0001 |
| Hemorrhagic | 74 (27.4) | 806 (40.3) | 0.68 (0.56-0.83) | p = 0.0002 |
| Cerebral venous thrombosis | 5 (1.9) | 60 (3) | 0.62 (0.25-1.5) | p = 0.29 |
| Comorbidities | ||||
| Hypertension | 105 (38.9) | 1180 (59) | 0.66 (0.56-0.77) | p < 0.0001 |
| Diabetes | 68 (25.2) | 515 (25.8) | 0.98 (0.78-1.21) | p = 0.84 |
| Dyslipidemia | 57 (21.1) | 318 (15.9) | 1.32 (1.03-1.7) | p = 0.027 |
| Alcohol use | 65 (24.1) | 323 (16.2) | 1.49 (1.18-1.88) | p = 0.0008 |
| Smoking | 86 (31.9) | 476 (23.8) | 1.34 (1.1-1.6) | p = 0.0028 |
| Obesity | 45 (16.7) | 540 (27) | 0.62 (0.47-0.81) | p = 0.0006 |
| Cardiac ischemic disease | 19 (7) | 180 (9) | 0.78 (0.49-1.23) | p = 0.28 |
Supplementary Table 1 Type of stroke (ischemic [n = 191], hemorrhagic [n = 74], cerebral venous thrombosis [n = 5]) presented according to the primary type of cancer (n = 270)
| Type of cancer | n (%) | Ischemic (%) | Hemorrhagic (%) | Cerebral Venous Thrombosis (%) |
|---|---|---|---|---|
| Gynecologic | 104 (38.5) | 83 (43.5) | 20 (27) | 1 (20) |
| Hematologic | 50 (18.5) | 26 (13.6) | 21 (28.4) | 3 (60) |
| Head and neck | 28 (10.4) | 21 (11) | 7 (9.5) | 0 |
| Lung | 21 (7.8) | 18 (9.4) | 3 (4.1) | 0 |
| Gastrointestinal | 22 (8.1) | 15 (7.9) | 7 (9.5) | 0 |
| Urologic | 30 (11.1) | 16 (8.4) | 13 (17.6) | 1 (20) |
| Soft tissue and skin | 14 (5.2) | 11 (5.8) | 3 (4.1) | 0 |
| Unknown | 1 (0.4) | 1 (0.5) | 0 | 0 |
Supplementary Table 2 Type of stroke (ischemic [n = 191], hemorrhagic [n = 74], cerebral venous thrombosis [n = 5]) presented according to group age (n = 270)
| Group age | n (%) | Ischemic (%) | Hemorrhagic (%) | Cerebral venous thrombosis (%) |
|---|---|---|---|---|
| < 45 years | 59 (21.9) | 25 (42.4) | 30 (50.8) | 4 (6.8) |
| 45-49 years | 90 (33.3) | 69 (76.7) | 20 (22.2) | 1 (1) |
| 60-74 years | 93 (34.4) | 73 (78.5) | 20 (21.5) | 0 |
| ≥ 75 years | 28 (1.4) | 24 (85.7) | 4 (14.3) | 0 |
Stroke risk factors that were more common in the cohort of patients without cancer were hypertension (p < 0.0001) and obesity (p = 0.0006), whereas dyslipidemia (p = 0.027), alcohol abuse (p = 0.0008), and tobacco use (p = 0.0028) were more frequent in the cohort of patients with cancer. Analysis of the cohorts based on the stroke type revealed that the rate of hemorrhagic stroke was higher in the cohort of patients without cancer (p = 0.0002) and that the rate of ischemic strokes was higher in the cancer cohort (p < 0.0001); however, no difference was observed in the rate of cerebral venous thrombosis between the two groups. The analysis of the 30-day mortality rates due to ischemic stroke, according to the TOAST (Trial of Org 10172 in acute stroke treatment)15 criteria in both cohorts, presented in table 2, revealed that there was no significant difference between the two cohorts. Table 3 presents 30-day, 90-day, 6-month, and 12-month mortality rates for ischemic stroke in both cohorts. Briefly, the mortality rates at 30 and 90 days were similar between the two cohorts; however, the 6-month and 12-month mortality rates were higher in the cohort of stroke patients with cancer than in the cohort of stroke patients without cancer (p < 0.001).
Table 2 30-day mortality among patients with ischemic stroke with cancer (n = 191) or without cancer (n = 981)13
| TOAST | Cancer patients n (%) | Non-cancer patients n (%) | RR (95% CI) | p value |
|---|---|---|---|---|
| Large Artery Atherosclerosis | 11/63 (17.5) | 8/84 (9.5) | 1.83 (0.78-4.3) | p = 0.16 |
| Lacunar | 2/24 (8.3) | 5/213 (2.5) | 3.55 (0.73-17.3) | p = 0.11 |
| Cardioembolism | 10/42 (23.8) | 44/188 (23.4) | 1.02 (0.56-1.85) | p = 0.96 |
| Undetermined | 8/27 (29.6) | 86/442 (19.5) | 1.52 (0.83-2.8) | p = 0.18 |
Table 3 Mortality frequency of patients with ischemic stroke with or without cancer13
| Mortality | Cancer patients n (%) | Non-cancer patients n (%) | RR (95% CI) | p value |
|---|---|---|---|---|
| 30 days | 32/191 (16.8) | 156/1040 (15) | 1.11 (0.79-1.6) | p = 0.53 |
| 90 days | 44/191 (23) | 178/937 (19) | 1.21 (0.91-1.6) | p = 0.19 |
| 6 months | 71/191 (37.2) | 196/854 (23) | 1.62 (1.3-2.02) | p < 0.0001 |
| 12 months | 82/191 (42.9) | 238/821 (29) | 1.48 (1.21-1.8) | p = 0.00001 |
Discussion
The comparison between 270 cancer patients who had a stroke and a cohort of 2000 stroke patients with no history of cancer from the same general population revealed that the frequency of ischemic stroke, along with the mid-term and long-term mortality rates were higher in the stroke patients with cancer. In addition, several variables associated with stroke, including alcoholism, tobacco use, and dyslipidemia were more common in the cohort of cancer patients with stroke compared to stroke patients.
One study reported that the typical risk factors for stroke were less common in cancer patients4, whereas others described that hypertension and dyslipidemia were the risk factors for stroke in this patient population6. In the current study, we found that dyslipidemia, smoking, and alcoholism were the risk factors for stroke that was more frequent in cancer patients with stroke than in stroke patients, which agrees with other studies others9. Cryptogenic stroke, observed more commonly in patients with occult cancer, with some studies reporting a frequency of 51%, was previously found to be associated with a poor prognosis11. In our analyses, the etiology of the stroke could not be determined despite comprehensive evaluation in almost 30% of the cancer patients with stroke.
In the general population, the mortality rates after an ischemic stroke were reported to be approximately 15%, 25%, and 50% at 1 month, 1 year, and 5 years, respectively2. The REVAMEVASC cohort12,13 presented lower mortality rates at 6-month and 12-month follow-up, suggesting worse mid-term and long-term prognoses for stroke patients with cancer and indicating the severe impact of stroke on survival in individuals that already have a life-threatening condition. A previous report demonstrated that patients who had the only stroke and later in life developed cancer had a worse prognosis during their clinical course16.
There are several limitations to the current study. First, a selection bias cannot be denied in this single-center study. To minimize information bias, the principal investigator (BCD) supervised all data. It must also be stated that this study did not use Chi-square or other comparative analyses since both database were independently acquired and were not paired for age, gender, or other condition. A future study would be ideal to compare these variables. Furthermore, Kaplan–Meier curves with log-rank to analyze survival are not reported, considering that access for information regarding survival or event-free survival in the RENAMEVASC database was not available. In spite of that, patients in both cohorts included in the current study share the same ethnic and demographic backgrounds, which is a strength of the study. Another major limitation was the lack of information regarding treatment and direct cause of death in many patients, which restrained our analysis.
Conclusion
Cancer and stroke are two common causes of mortality that often occur concomitantly. The frequency of ischemic stroke and the mid-term and long-term mortality rates were higher in stroke patients with cancer compared with a cohort of stroke patients with no history of cancer that shared the same sociodemographic characteristics, which should be confirmed with future, large-scale studies.
